<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409876</url>
  </required_header>
  <id_info>
    <org_study_id>HistoBrachy1</org_study_id>
    <nct_id>NCT01409876</nct_id>
  </id_info>
  <brief_title>HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy</brief_title>
  <official_title>HistoScanning- Based Dose-painting Image-guided Interstitial PDR-brachytherapy in Prostate Cancer - a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <brief_summary>
    <textblock>
      This is a phase II trial looking at the feasibility of HistoScanning- based dose-painting
      image- guided interstitial brachytherapy in non- metastatic prostate cancer

      Endpoints:

      Primary endpoint Evaluation of the feasibility of HistoScanning- based dose-painting image-
      guided interstitial brachytherapy

      Secondary endpoints

        1. Evaluating tumor response using HistoScanning

        2. Evaluating locoregional recurrence rates by measuring PSA

        3. Analysis of the correlation between tumor response as determined by HistoScanning and
           PSA response

        4. Evaluating the safety dose-painting image- guided interstitial brachytherapy by
           recording serious adverse events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      The study is designed as a prospective monocentric phase II trial. The choice of the
      therapeutic concept is governed by the risk group that the patient falls into. Risk groups
      are defined according to the classification by D' Amico.

      The following concepts will be used:

      HDR brachytherapy: 19,0- 38 Gy / 2-4 fractions (2-4 x 9,5 Gy)

      PDR brachytherapy: 35-70 Gy / 50 --100 pulses(1 puls/h, 24 h/d)

      Dose painting the timorous areas as seen in HistoScanning as covered with a dose
      Dref2&gt;130-150%

      External beam radiotherapy will be used in addition to brachytherapy for intermediate and
      high risk patients. The following concepts will be used 50,40 Gy / 28 fractions at 1.8 Gy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the feasibilty of histoscanning- based dose-painting image- guided interstitial brachytherapy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessing tumor response and side effects</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>interstitial image- guided PDR/HDR brachytherapy</description>
    <arm_group_label>Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven prostate cancer

          -  All cT1-3 carcinomas independent of grading and PSA value

          -  Prostate volume&lt; 70cc

          -  No distant metastases

          -  Karnofsky &gt; 60

          -  Written informed consent from the patient regarding study participation

        Exclusion criteria:

          -  All patients who do not meet the inclusion criteria

          -  T4 carcinomas

          -  Proven metastases N+ and/or M1

          -  Epidural or general anaesthesia not possible

          -  Pathological clotting parameters
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Lettmaier, MD</last_name>
    <phone>09131 85 44216</phone>
    <email>sebastianlettmaier@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Therapy University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vratislav Strnad, MD, Prof</last_name>
      <phone>+49 9131 85 33419</phone>
      <email>vratislav.strnad@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sebastian Lettmaier</name_title>
    <organization>University Hospital Erlangen</organization>
  </responsible_party>
  <keyword>histoscanning</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

